Search Results - "VESCIO, Robert"

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial by Lonial, Sagar, Prof, Weiss, Brendan M, Prof, Usmani, Saad Z, Prof, Singhal, Seema, Prof, Chari, Ajai, Prof, Bahlis, Nizar J, Prof, Belch, Andrew, Prof, Krishnan, Amrita, Prof, Vescio, Robert A, Prof, Mateos, Maria Victoria, Prof, Mazumder, Amitabha, Prof, Orlowski, Robert Z, Prof, Sutherland, Heather J, Prof, Bladé, Joan, Prof, Scott, Emma C, Prof, Oriol, Albert, MD, Berdeja, Jesus, MD, Gharibo, Mecide, Prof, Stevens, Don A, MD, LeBlanc, Richard, Prof, Sebag, Michael, Prof, Callander, Natalie, Prof, Jakubowiak, Andrzej, Prof, White, Darrell, Prof, de la Rubia, Javier, Prof, Richardson, Paul G, Prof, Lisby, Steen, MD, Feng, Huaibao, PhD, Uhlar, Clarissa M, PhD, Khan, Imran, MD, Ahmadi, Tahamtan, MD, Voorhees, Peter M, Prof

“…Summary Background New treatment options are needed for patients with multiple myeloma that is refractory to proteasome inhibitors and immunomodulatory drugs…”
Get full text

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study by Kumar, Shaji K, Prof, Berdeja, Jesus G, MD, Niesvizky, Ruben, Prof, Lonial, Sagar, Prof, Laubach, Jacob P, MD, Hamadani, Mehdi, MD, Stewart, A Keith, Prof, Hari, Parameswaran, Prof, Roy, Vivek, MD, Vescio, Robert, MD, Kaufman, Jonathan L, MD, Berg, Deborah, MSN, Liao, Eileen, PhD, Di Bacco, Alessandra, PhD, Estevam, Jose, BSc, Gupta, Neeraj, PhD, Hui, Ai-Min, MD, Rajkumar, Vincent, Prof, Richardson, Paul G, Prof

“…Summary Background The combination of bortezomib, lenalidomide, and dexamethasone is a highly effective therapy for newly diagnosed multiple myeloma. Ixazomib…”
Get full text

Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival by Sanchez, Eric, Li, Mingjie, Kitto, Alex, Li, Jennifer, Wang, Cathy S., Kirk, Dylan T., Yellin, Ori, Nichols, Cydney M., Dreyer, Marissa P., Ahles, Cameryn P., Robinson, Austin, Madden, Erik, Waterman, Gabriel N., Swift, Regina A., Bonavida, Benjamin, Boccia, Ralph, Vescio, Robert A., Crowley, John, Chen, Haiming, Berenson, James R.

“…Summary Although TNFRSF17 (also designated as B‐cell maturation antigen (BCMA)) is expressed on tumour cells in B‐cell malignancies, it has not been found in…”
Get full text

Irradiated Bone Marrow Volume is Associated With Hematologic Toxicity in Patients With Multiple Myeloma by Zhang, Samuel C., Kim, Sungjin, Steers, Jennifer, Stiehl, Bradley, Silos, Katrina D., Grigsby, Giana, Oorloff, Maria, Upadhaya, Taman, Vescio, Robert A., Oveisi, David R., Hakimian, Behrooz, Atkins, Katelyn M., Ballas, Leslie K.

“…Palliative radiation therapy (RT) is effective for multiple myeloma (MM) but may cause cytopenia. Bone marrow volume receiving 10 Gy (BMV10Gy) has been…”
Get full text

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma by Ailawadhi, Sikander, Kelly, Kevin R., Vescio, Robert A., Jagannath, Sundar, Wolf, Jeffrey, Gharibo, Mecide, Sher, Taimur, Bojanini, Leyla, Kirby, Maurice, Chanan-Khan, Asher

“…Lorvotuzumab mertansine, a unique antibody–drug conjugate targeting CD56, is frequently expressed on multiple myeloma cells. The present phase I trial of the…”
Get full text

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study by Reece, Donna E., Hegenbart, Ute, Sanchorawala, Vaishali, Merlini, Giampaolo, Palladini, Giovanni, Bladé, Joan, Fermand, Jean-Paul, Hassoun, Hani, Heffner, Leonard, Vescio, Robert A., Liu, Kevin, Enny, Christopher, Esseltine, Dixie-Lee, van de Velde, Helgi, Cakana, Andrew, Comenzo, Raymond L.

“…This first prospective phase 2 study of single-agent bortezomib in relapsed primary systemic AL amyloidosis evaluated the recommended (maximum planned) doses…”
Get full text

Development of the Histoculture Drug Response Assay (HDRA) by Hoffman, Robert M, Vescio, Robert A

“…The histoculture drug response assay (HDRA) was developed using Gelfoam histoculture of all tumor types. Twenty tumor classes, including all the major ones,…”
Get more information

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis by Reece, Donna E., Hegenbart, Ute, Sanchorawala, Vaishali, Merlini, Giampaolo, Palladini, Giovanni, Bladé, Joan, Fermand, Jean-Paul, Hassoun, Hani, Heffner, Leonard, Kukreti, Vishal, Vescio, Robert A., Pei, Lixia, Enny, Christopher, Esseltine, Dixie-Lee, van de Velde, Helgi, Cakana, Andrew, Comenzo, Raymond L.

“…CAN2007 was a phase 1/2 study of once- and twice-weekly single-agent bortezomib in relapsed primary systemic amyloid light chain amyloidosis (AL) amyloidosis…”
Get full text

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study by Reece, Donna E., Sanchorawala, Vaishali, Hegenbart, Ute, Merlini, Giampaolo, Palladini, Giovanni, Fermand, Jean-Paul, Vescio, Robert A., Liu, Xiangyang, Elsayed, Yusri A., Cakana, Andrew, Comenzo, Raymond L.

“…New treatment options are required for primary systemic AL amyloidosis (AL). This phase 1 dose-escalation component of a phase 1/2 study in relapsed AL aimed…”
Get full text

Phase I/II Trial Assessing Bortezomib and Melphalan Combination Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma by BERENSON, James R, YANG, Hank H, ADAMS, Julian, SCHENKEIN, David, SWIFT, Regina, SADLER, Karen, JARUTIRASARN, Supol G, VESCIO, Robert A, MAPES, Russell, PURNER, Matthew, LEE, Shi-Pyng, WILSON, Joanna, MORRISON, Blake

“…Bortezomib has shown synergy with melphalan in preclinical models. We assessed the safety, tolerability, and response rate in a dose-escalation study of this…”
Get full text

The Proteasome Inhibitor PS-341 Markedly Enhances Sensitivity of Multiple Myeloma Tumor Cells to Chemotherapeutic Agents by MA, Mark H, YANG, Hank H, NEESER, Jason, MIKAIL, Amy, ADAMS, Julian, SJAK-SHIE, Nelida, VESCIO, Robert A, BERENSON, James R, PARKER, Kimberly, MANYAK, Steven, FRIEDMAN, Jeffrey M, ALTAMIRANO, Cibby, WU, Zhi-Qun, BORAD, Mitesh J, FRANTZEN, Malka, ROUSSOS, Evanthia

“…Increased nuclear factor κB (NF-κB) activity is associated with increased tumor cell survival in multiple myeloma. The function of NF-κB is inhibited through…”
Get full text

Safety of bloodless autologous stem cell transplantation in Jehovah's Witness patients by Beck, Alyssa, Lin, Robert, Reza Rejali, Ali, Rubens, Muni, Paquette, Ronald, Vescio, Robert, Merin, Noah, Guerrero, Margarita, Federizo, Yvette, Lua, Michelle, Uy, Leticia, Hernandez, Lorraine, Allred, Mohana, Legaspi, Ronald, Leaverton, Melissa, Oliva, Sara, Castillo, Rhona, Dean, Lorna, Bourke, Jennifer, Cooper, Sara, Gharapetian, Seda, Causin, Jose, Lopiccolo, Christopher, Ann Snoussi, Laura, VanStrien, Patricia, Lill, Michael, Linhares, Yuliya P.

“…Due to the curative potential and improvement in progression-free survival (PFS), high-dose chemotherapy followed by autologous stem cell transplantation…”
Get full text

Low booster uptake in cancer patients despite health benefits by Figueiredo, Jane C., Levy, Julia, Choi, So Yung, Xu, Alexander M., Merin, Noah M., Hamid, Omid, Lemos, Tucker, Nguyen, Nathalie, Nadri, Maimoona, Gonzalez, Alma, Mahov, Simeon, Darrah, Justin M., Gong, Jun, Paquette, Ronald L., Mita, Alain C., Vescio, Robert A., Salvy, Sarah J., Mehmi, Inderjit, Hendifar, Andrew E., Natale, Ronald, Tourtellotte, Warren G., Ramanujan, V. Krishnan, Huynh, Carissa A., Sobhani, Kimia, Reckamp, Karen L., Merchant, Akil A.

“…Patients with cancer are at increased risk of death from COVID-19 and have reduced immune responses to SARS-CoV2 vaccines, necessitating regular boosters. We…”
Get full text

An open‐label, phase 2 trial of denosumab in the treatment of relapsed or plateau‐phase multiple myeloma by Vij, Ravi, Horvath, Noemi, Spencer, Andrew, Taylor, Kerry, Vadhan‐Raj, Saroj, Vescio, Robert, Smith, Judy, Qian, Yi, Yeh, Howard, Jun, Susie

“…RANKL is a key mediator of osteoclast differentiation, activation, and survival. Preclinical data suggest that aberrant production and activation of…”
Get full text

Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution by DOUEK, D. C, VESCIO, R. A, BETTS, M. R, BRENCHLEY, J. M, HILL, B. J, LAN ZHANG, BERENSON, J. R, COLLINS, R. H, KOUP, R. A

“…The potential benefits of haematopoietic stem-cell transplantation are tempered by the depletion of T-cells accompanying this procedure. We used a new…”
Get full text

Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis by YANG, Hank H, MA, Mark H, VESCIO, Robert A, BERENSON, James R

“…Drug resistance remains a major clinical challenge for cancer treatment. Early studies suggested that overexpression of P-glycoprotein was a major contributor…”
Get full text

Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group by VON PAWEL, J, VON ROEMELING, R, OLVER, I, BERGMAN, B, AYOUB, J, RICHARDSON, G, DUNLOP, D, ARCENAS, A, VESCIO, R, VIALLET, J, TREAT, J, GATZEMEIER, U, BOYER, M, ELISSON, L. O, CLARK, P, TALBOT, D, REY, A, BUTLER, T. W, HIRSH, V

“…PURPOSE: A phase III trial, Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non–Small-Cell Lung Tumors (CATAPULT I), was designed to…”
Get full text

Phase 2 study of two sequential three‐drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma by Bensinger, William I., Jagannath, Sundar, Vescio, Robert, Camacho, Elber, Wolf, Jeffrey, Irwin, David, Capo, Gerardo, McKinley, Marti, Potts, Phyllis, Vesole, David H., Mazumder, Amitabha, Crowley, John, Becker, Pam, Hilger, Jacqueline, Durie, Brian G.M.

“…Summary Novel sequential combination therapy for induction may improve the quality of response and therefore prolong survival in newly diagnosed multiple…”
Get full text

Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up by Berenson, James R., Yang, Hank H., Vescio, Robert A., Nassir, Youram, Mapes, Russell, Lee, Shi-pyng, Wilson, Joanna, Yellin, Ori, Morrison, Blake, Hilger, Jacqueline, Swift, Regina

“…Bortezomib synergizes with melphalan in preclinical and early clinical studies. Updated data from our phase 1/2 study assessing the safety and efficacy of…”
Get full text

Purging of Autologous Peripheral-Blood Stem Cells Using CD34 Selection Does Not Improve Overall or Progression-Free Survival After High-Dose Chemotherapy for Multiple Myeloma: Results of a Multicenter Randomized Controlled Trial by STEWART, A. Keith, VESCIO, Robert, STIFF, Pat, MEHARCHARD, Jacinta, SCHLOSSMAN, Robert, BROWN, Randy, TULLY, Heather, BENYUNES, Mark, JACOBS, Cindy, BERENSON, Ronald, WHITE, Michael, DIPERSIO, John, SCHILLER, Gary, ANDERSON, Kenneth C, BERENSON, James, BALLESTER, Oscar, NOGA, Stephen, RUGO, Hope, FREYTES, Cesar, STADTMAUER, Edward, TARANTOLO, Stefano, SAHEBI, Firoozeh

“…Although high-dose chemotherapy supported by autologous peripheral-blood progenitor-cell (PBPC) transplantation improves response rates and survival for…”
Get full text